Bifogade filer
Kurs
+6,19%
Likviditet
0,06 MSEK
Prenumeration
Kalender
Tid* | ||
2025-08-29 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-28 | N/A | Årsstämma |
2025-04-25 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-02-14 | 08:30 | Bokslutskommuniké 2024 |
2024-11-01 | - | Kvartalsrapport 2024-Q3 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2024-05-30 | - | Årsstämma |
2024-04-26 | - | Kvartalsrapport 2024-Q1 |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-12-21 | - | Extra Bolagsstämma 2024 |
2023-11-17 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-04-06 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2023-04-05 | - | Årsstämma |
2023-02-03 | - | Bokslutskommuniké 2022 |
2022-11-07 | - | Kvartalsrapport 2022-Q3 |
2022-10-05 | - | Extra Bolagsstämma 2022 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-06-15 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2022-06-14 | - | Årsstämma |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-02-18 | - | Bokslutskommuniké 2021 |
2021-11-29 | - | Kvartalsrapport 2021-Q3 |
2021-09-23 | - | Extra Bolagsstämma 2021 |
2021-08-30 | - | Kvartalsrapport 2021-Q2 |
2021-06-28 | - | Årsstämma |
2021-06-15 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-11-09 | - | Kvartalsrapport 2020-Q3 |
2020-08-17 | - | Kvartalsrapport 2020-Q2 |
2020-06-26 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2020-06-25 | - | Årsstämma |
2020-05-11 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-05-10 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2019-05-06 | - | Kvartalsrapport 2019-Q1 |
2019-04-10 | - | Årsstämma |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-12-18 | - | Extra Bolagsstämma 2018 |
2018-10-24 | - | Kvartalsrapport 2018-Q3 |
2018-08-29 | - | Kvartalsrapport 2018-Q2 |
2018-05-24 | - | Kvartalsrapport 2018-Q1 |
2018-04-12 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2018-04-11 | - | Årsstämma |
2018-03-22 | - | Bokslutskommuniké 2017 |
2017-08-29 | - | Kvartalsrapport 2017-Q2 |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-04-26 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2017-04-25 | - | Årsstämma |
2017-02-24 | - | Bokslutskommuniké 2016 |
2016-11-16 | - | Kvartalsrapport 2016-Q3 |
2016-10-19 | - | Extra Bolagsstämma 2016 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-04-20 | - | Kvartalsrapport 2016-Q1 |
2016-02-25 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2016-02-24 | - | Årsstämma |
2016-02-04 | - | Bokslutskommuniké 2015 |
2015-11-13 | - | Kvartalsrapport 2015-Q3 |
2015-09-04 | - | Kvartalsrapport 2015-Q2 |
2015-07-22 | - | Extra Bolagsstämma 2015 |
2015-05-07 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2015-05-06 | - | Årsstämma |
2015-04-17 | - | Kvartalsrapport 2015-Q1 |
2015-02-20 | - | Bokslutskommuniké 2014 |
2014-12-17 | - | Extra Bolagsstämma 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-11-14 | - | Kvartalsrapport 2014-Q3 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-06-12 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2014-06-11 | - | Årsstämma |
2014-05-16 | - | Kvartalsrapport 2014-Q1 |
2014-02-21 | - | Bokslutskommuniké 2013 |
2013-11-15 | - | Kvartalsrapport 2013-Q3 |
2013-08-28 | - | Kvartalsrapport 2013-Q2 |
2013-06-17 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2013-06-14 | - | Årsstämma |
2013-05-17 | - | Kvartalsrapport 2013-Q1 |
2013-02-22 | - | Bokslutskommuniké 2012 |
2012-11-30 | - | Kvartalsrapport 2012-Q3 |
2012-07-31 | - | Kvartalsrapport 2012-Q2 |
2012-06-20 | - | X-dag ordinarie utdelning IZAFE B 0.00 SEK |
2012-06-19 | - | Årsstämma |
2012-04-20 | - | Kvartalsrapport 2012-Q1 |
2012-02-21 | - | Bokslutskommuniké 2011 |
2011-11-04 | - | Kvartalsrapport 2011-Q3 |
2011-08-12 | - | Kvartalsrapport 2011-Q2 |
2011-05-06 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
iZafe Group AB announces that its product, Dosell, is now certified for integration with Enovation UMO, the monitoring solution for medical service centres. Enovation UMO is part of Enovation Platform, a leading platform for digital care and collaboration used in over 18 countries. This certification marks a significant milestone for iZafe and enables strategically important expansion in both established and new markets.
A Long-Awaited Solution for Dutch Partners
The certification has been highly anticipated by iZafe's partners in the Netherlands, where Enovation UMO is a well-established standard in healthcare. These partners have been eager to begin selling Dosell and can now leverage the seamless integration with the UMO platform. This ensures that Dosell not only complements but also enhances their offering by providing a comprehensive solution for medication management, alarms, and other digital healthcare services within the same platform.
"Creating a Unique Market Position"
"This certification is a critical milestone for iZafe and our partners, especially in the Dutch market, where interest in Dosell is substantial," says Anders Segerström, CEO of iZafe Group AB. "Dosell is specifically designed to be part of a healthcare technology ecosystem, and integrations like this not only simplify implementation but also improve the experience for both users and caregivers."
Benefits of an Integrated Ecosystem
By becoming certified on Enovation UMO, Dosell establishes a unique market position. Offering an integrated solution that handles medication management, alarms, and other care needs within a single platform meets the growing demand for comprehensive solutions in digital healthcare. This not only enhances iZafe's appeal to healthcare providers but also enables its partners to deliver a more competitive and value-driven offering to their customers.
Opening Doors to More Markets
Beyond the Netherlands, this integration also creates opportunities for iZafe to expand into other markets where Enovation UMO is established. With the platform’s presence in 18 countries, iZafe has a unique opportunity to strengthen its international presence and build relationships with new partners and customers.
A Step Forward for iZafe’s Growth Strategy
The certification is part of iZafe’s broader strategy to establish Dosell as a key component of the global healthcare technology landscape. By collaborating with established platforms like Enovation UMO, iZafe demonstrates its commitment to innovation and its ability to meet market demands for integrated and efficient healthcare solutions.
About Enovation Platform
Enovation UMO is part of the Enovation Platform: the leading platform for digital care and collaboration. With over 350 partners worldwide, the platform offers a wide variety of integrations. Enovation Platform uses open software, which connects seamlessly to care organisations' systems and those of their partner organisations. This way, the platform provides all the digital tools care professionals need to support patients or clients – whatever their needs.
https://enovationgroup.com/en/enovation-umo/
Contacts
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm
E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group
About iZafe Group AB (publ.)
iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.
The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.
The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.
iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com